Shaanxi Meibang Pharmaceutical Group Co., Ltd. (SHA:605033)
China · Delayed Price · Currency is CNY 19.15
-0.44 (-2.25%)
Aug 17, 2026, 3:00 PM CST
SHA:605033 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 978.45 | 908.84 | 881.01 | 694.02 | 905.41 | 841.93 |
Other Revenue | 3.11 | 3.11 | 4.52 | 5.01 | 0.63 | 0.56 |
| 981.56 | 911.95 | 885.53 | 699.03 | 906.05 | 842.49 | |
Revenue Growth | 13.97% | 2.98% | 26.68% | -22.85% | 7.54% | 48.19% |
Cost of Revenue | 647.27 | 619.2 | 654.14 | 478.04 | 528.82 | 532.38 |
Gross Profit | 334.29 | 292.75 | 231.39 | 220.99 | 377.23 | 310.11 |
Selling, General & Admin | 177.26 | 163.42 | 141.19 | 119.27 | 153.18 | 116.7 |
Research & Development | 86.24 | 84.93 | 74.33 | 58.53 | 80.04 | 63.81 |
Other Operating Expenses | 1.88 | 2.73 | 2.23 | 2.75 | 3.45 | 2.9 |
Operating Expenses | 266.58 | 250.35 | 212.51 | 178.09 | 242.66 | 187.05 |
Operating Income | 67.71 | 42.4 | 18.88 | 42.9 | 134.57 | 123.06 |
Interest Expense | -0.72 | -0.4 | -0.01 | -0.38 | -0.98 | -3.31 |
Interest & Investment Income | 7.19 | 7.41 | 9.33 | 6.58 | 6.86 | 2.61 |
Currency Exchange Gain (Loss) | -0.01 | 0.01 | 0.02 | 0 | - | 0.06 |
Other Non Operating Income (Expenses) | -1.18 | -0.23 | -0.15 | -0.13 | -0.11 | 0.08 |
EBT Excluding Unusual Items | 72.98 | 49.2 | 28.07 | 48.97 | 140.34 | 122.5 |
Gain (Loss) on Sale of Investments | 0.84 | 0.87 | 0.47 | - | -0.07 | - |
Gain (Loss) on Sale of Assets | 0.19 | 0.19 | -0.03 | -0.04 | -0.12 | -0.02 |
Asset Writedown | -1.86 | -1.86 | - | 0.01 | - | - |
Other Unusual Items | 3.99 | 3.99 | 9.35 | 13.47 | 12.21 | 16.35 |
Pretax Income | 76.13 | 52.37 | 37.86 | 62.41 | 152.37 | 138.83 |
Income Tax Expense | 12.54 | 3.71 | 1 | 4.85 | 7.28 | 13.09 |
Net Income | 63.59 | 48.66 | 36.86 | 57.56 | 145.09 | 125.74 |
Net Income to Common | 63.59 | 48.66 | 36.86 | 57.56 | 145.09 | 125.74 |
Net Income Growth | 148.72% | 32.03% | -35.96% | -60.33% | 15.38% | 59.70% |
Shares Outstanding (Basic) | 135 | 135 | 137 | 134 | 136 | 110 |
Shares Outstanding (Diluted) | 135 | 135 | 137 | 134 | 136 | 110 |
Shares Change | -0.17% | -0.98% | 1.99% | -1.29% | 22.93% | 9.27% |
EPS (Basic) | 0.47 | 0.36 | 0.27 | 0.43 | 1.07 | 1.14 |
EPS (Diluted) | 0.47 | 0.36 | 0.27 | 0.43 | 1.07 | 1.14 |
EPS Growth | 149.14% | 33.33% | -37.21% | -59.81% | -6.14% | 46.15% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -32.73 | 44.74 | 121.59 | 131.1 | 17.12 | -215.28 |
Free Cash Flow Per Share | -0.24 | 0.33 | 0.89 | 0.98 | 0.13 | -1.95 |
Dividend Per Share | 0.100 | 0.150 | 0.145 | 0.150 | 0.220 | 0.190 |
Dividend Growth | -33.33% | 3.45% | -3.33% | -31.82% | 15.79% | - |
Gross Margin | 34.06% | 32.10% | 26.13% | 31.61% | 41.63% | 36.81% |
Operating Margin | 6.90% | 4.65% | 2.13% | 6.14% | 14.85% | 14.61% |
Profit Margin | 6.48% | 5.34% | 4.16% | 8.23% | 16.01% | 14.92% |
Free Cash Flow Margin | -3.33% | 4.91% | 13.73% | 18.75% | 1.89% | -25.55% |
EBITDA | 106.22 | 73.6 | 40.63 | 63.77 | 150.05 | 135.54 |
EBITDA Margin | 10.82% | 8.07% | 4.59% | 9.12% | 16.56% | 16.09% |
D&A For EBITDA | 38.5 | 31.2 | 21.75 | 20.87 | 15.47 | 12.48 |
EBIT | 67.71 | 42.4 | 18.88 | 42.9 | 134.57 | 123.06 |
EBIT Margin | 6.90% | 4.65% | 2.13% | 6.14% | 14.85% | 14.61% |
Effective Tax Rate | 16.47% | 7.08% | 2.64% | 7.78% | 4.78% | 9.43% |
Revenue as Reported | 981.56 | 911.95 | 885.53 | 699.03 | 906.05 | 842.49 |
Advertising Expenses | - | 18.19 | 17.2 | 10.78 | 27.33 | 11.56 |